The latest biotech news

bayer ginkgo bioworks plant microbiome biotech

News and Trends 15 Sep 2017

Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A

Bayer and Ginkgo Bioworks are launching a new company that will develop new technologies for sustainable agriculture by engineering the plant microbiome. With the microbiome already gaining traction in the therapeutics field, Bayer has decided to take it to agriculture. In partnership with US synthetic biology upstart Ginkgo Bioworks, the German giant is creating a new […]

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Sep 2017

A Swedish-Spanish Team Takes on a New Immuno-Oncology Target

Alligator Bioscience will collaborate with the University of Navarra, Spain, to study the potential of CD137 as a target for new cancer immunotherapies. Alligator Bioscience, based in Lund, Sweden, has teamed up with Prof. Ignacio Melero at the Center for Applied Medical Research (CIMA) at the University of Navarra to study the biological effects of activating […]

September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Sep 2017

Italian Biotech Closes €7M Series B for Stem Cells to Treat Cancer

Genenta Science has raised $8M (€7M) in the Series B fundraising round to continue investigating its use of hematopoietic stem cells to treat cancer. Based in Milan, Genenta can add €7M to the €10M secured in Series A of fundraising. Italian, British and Swiss private investors led the investment, and it will allow the biotech to start a second […]

September 13, 2017 - 2 minutesmins - By Alex Dale

News and Trends 13 Sep 2017

Epigenetics Drug Proves Effective in Phase I for Lethal Cancer

4SC’s partner Yakult Honsha has presented positive results at ESMO 2017 for the epigenetics drug resminostat in a Phase I trial run in Japan. The histone deacetylase (HDAC) inhibitor resminostat has shown to induce tumor shrinkage or disease stabilization in all patients with biliary tract cancer in a Phase I trial. The goal was to determine […]

September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Sophia Genetics artificial intelligence fundraising

News and Trends 13 Sep 2017

Series D Boost will Bring Artificial Intelligence to Diagnostics Worldwide

Sophia Genetics has raised $30M (€25M) in Series D that will be directed to growing and improving its artificial intelligence platform for genetic diagnostics. The Swiss company Sophia Genetics has announced today a new round of funding, led by Balderton Capital, and joined by 360º Capital Partners and existing investors Invoke Capital and Alychlo. The […]

September 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Sep 2017

What You Need to Know About the EU’s New Data Protection Law

The EU’s new data protection law is going to have a great impact on companies worldwide, including those involved in clinical trials. Here’s what you have to know and how to act! In May 2018, the European Union’s new data protection law, the General Data Protection Regulation (GDPR), is set to replace the current Data […]

September 13, 2017 - 13 minutesmins - By External Contributor

News and Trends 12 Sep 2017

France Invests €15M in Developing a New Generation of Antibiotics

Deinove has received funding from Bpifrance to work on the discovery of the next generation of antibiotics to fight antibiotic-resistant pathogens. The Investments for the Future Program, operated by the French public investment bank Bpifrance, has granted €14.6M to the Antibiotics against Resistant Infectious Germs (AGIR) project, carried out by the Deinove group in collaboration […]

September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Sep 2017

Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine

PCI Biotech’s T cell-stimulating vaccine enhances the cellular immune response, supporting it as a candidate for use alongside cancer vaccines. PCI Biotech, based in Oslo, Norway, has seen positive initial results in an ongoing Phase I trial for its firmaVacc technology. The trial is being carried out in 110 healthy subjects, and it aims to […]

September 12, 2017 - 2 minutesmins - By Alex Dale

News and Trends 12 Sep 2017

British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic

Summit Therapeutics has been awarded the Barda Contract worth up to $62M (€52M) to continue to the development of a new antibiotic for hospital-acquired infections. Summit Therapeutics, a biopharma company operating in the UK and US, has received the Barda Contract, designed to counter public health emergencies. In this case, the money will help to […]

September 12, 2017 - 3 minutesmins - By Alex Dale

News and Trends 12 Sep 2017

French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III

Onxeo has announced Phase III results for its nanoparticle chemotherapy Livatag, which failed to improve the outcome for patients with hepatocellular carcinoma compared to other available treatments. The stock of the French oncology specialist Onxeo was halved this morning when it revealed the results of a Phase III trial with its candidate Livatag that failed to […]

September 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Sep 2017

French Startup Raises €11M in Series A to Reinvent DNA Synthesis

DNA Script has gathered the support of key international investors to take a new, faster DNA synthesis technology closer to the market. In a Series A round led by Illumina Ventures and joined by Merck Ventures and existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners, the young French startup DNA Script has raised a total […]

September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

imfinzi astrazeneca breakthrough designation

News and Trends 11 Sep 2017

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

UPDATE: 11/09/2017: AstraZeneca has presented impressive results at ESMO that show Imfinzi adding 11 months to patient survival, or decreasing the risk of progression by 48%, in Stage 3 NSCLC. This indication represents a sizable market segment — about half of lung cancer — and Imfinzi’s first-line position could make it a blockbuster. Original Publication: […]

September 11, 2017 - 2 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A

A Swedish-Spanish Team Takes on a New Immuno-Oncology Target

Italian Biotech Closes €7M Series B for Stem Cells to Treat Cancer

Epigenetics Drug Proves Effective in Phase I for Lethal Cancer

Series D Boost will Bring Artificial Intelligence to Diagnostics Worldwide

What You Need to Know About the EU’s New Data Protection Law

France Invests €15M in Developing a New Generation of Antibiotics

Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine

British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic

French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III

French Startup Raises €11M in Series A to Reinvent DNA Synthesis

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!